Alzheimer’s Breakthrough Meets The Budget Wall

A medical breakthrough can still fail at the pharmacy counter. We finally have amyloid-targeting drugs for early-stage Alzheimer’s disease, and they are already on the market, but several major health systems have looked at the same evidence and refused to pay. That contradiction is the mystery we unpack, using the explosive Glasgow IPCAD meeting as our guide to what’s really blocking access.

We dig into the three barriers driving negative reimbursement decisions: headline drug prices, serious safety risks that require ongoing MRI monitoring, and the hardest problem of all, long-term efficacy. When trials last about 18 months, payers are forced to guess whether small changes in cognitive scores translate into years of real independence. From there, we explore the new toolkit health economists are building, including AI-supported micro-simulation models that create thousands of virtual patients and project outcomes decades into the future.

The conversation turns practical fast. We explain why caregiver burden and caregiver quality of life can change the math, why biomarker diagnostics like PET scans and lumbar punctures can bankrupt a system before the first dose, and how real-world evidence programs like coverage with evidence development try to balance access with learning. We also look at global registry efforts such as INRAD that standardize data across borders, then confront the uncomfortable truth: even if the money shows up, many countries lack the infusion clinics, diagnostic capacity, and specialist workforce to deliver these therapies at scale.

We close with a provocative question about the near future of blood-based screening and presymptomatic diagnosis, and what it means to know you’re at risk while treatment remains financially out of reach. If this helped you think differently about Alzheimer’s policy, health economics, and brain health, subscribe, share the episode, and leave a review so more people can find it.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Transcript

Breakthrough Meets Reimbursement Wall

SPEAKER_01 0:00

After um decades of heartbreaking setbacks, I mean literally billions of dollars in research, science has finally delivered something huge.

SPEAKER_00 0:10

Yeah, it really is a monumental shift.

SPEAKER_01 0:12

Exactly. We finally have the very first amyloid-targeting drugs for early stage Alzheimer's disease. They're out of the lab. They are on the market right now, you know, in multiple countries around the world.

SPEAKER_00 0:24

Right. It's not hypothetical anymore.

SPEAKER_01 0:25

Aaron Ross Powell But and this is a massive but for you listening, if you happen to live in the UK or France or Australia, your major health systems have looked at this huge scientific triumph and just said, no, we won't pay for them.

SPEAKER_00 0:39

Aaron Powell Which is uh staggering when you think about the clinical need.

SPEAKER_01 0:43

Aaron Powell It is.

Inside The Glasgow Crisis Summit

SPEAKER_01 0:44

So to understand why a historic medical breakthrough is colliding with like the total economic brick wall, we have to look at what happened behind closed doors at a very specific, highly pivotal gathering.

SPEAKER_00 0:54

Aaron Powell Right, the Glasgow meeting.

SPEAKER_01 0:56

Yes. For today's deep dive, we are looking at a 2026 letter to the editor from the Journal of Prevention of Alzheimer's Disease. It details the explosive proceedings of the ninth IPCAD meeting. That stands for the uh International Pharmacoeconomic Collaboration on Alzheimer's Disease.

SPEAKER_00 1:14

Held in Glasgow, Scotland, right at the end of 2025.

SPEAKER_01 1:17

Aaron Ross Powell Exactly. And our mission today is to figure out exactly why this bottleneck is happening and how this whole global network of health economists, patient groups, and regulators is scrambling to fix it.

SPEAKER_00 1:29

Aaron Powell Because it was essentially a crisis summit. You had the brightest minds in academia, industry, patient organizations all converging to figure this out.

SPEAKER_01 1:36

Aaron Powell Because the science worked, but the system didn't.

SPEAKER_00 1:38

Aaron Powell Exactly. We finally have a pharmacological intervention that targets the underlying mechanism of the disease rather than just managing the symptoms. And yet the appraisal processes in major health systems are resulting in negative reimbursement decisions. It really highlights this a harsh reality that the journey of a breakthrough doesn't end at the laboratory door. It crashes headfirst into the really complex machinery of how we actually value human health.

SPEAKER_01 2:07

And the source material lays out exactly what is jamming up

The Three Barriers To Coverage

SPEAKER_01 2:10

those gears. Governments are looking at these new therapies and citing a few like massive concerns for refusing to fund them.

SPEAKER_00 2:18

Yeah, there are three main hurdles they bring up.

SPEAKER_01 2:20

Aaron Powell Right. So first, the basic math. They're saying the current cost of the drugs just outweighs the proven benefits. Second, there are significant safety considerations. We're talking about very serious side effects like brain swelling and bleeding. Trevor Burrus, Jr.

SPEAKER_00 2:33

Which obviously requires intense monitoring.

SPEAKER_01 2:35

Oh, absolutely. Yeah. But the third reason is what we really need to focus on today. It's this massive blind spot regarding long-term efficacy.

SPEAKER_00 2:41

Aaron Powell That blind spot is really driving the entire funding crisis. Health systems are basically being asked to commit vast ongoing resources based on extremely limited temporal data.

SPEAKER_01 2:52

Aaron Powell Okay, let's unpack this because this is where the pushback really starts. Let's look at what these drugs actually do. They target amyloid, right? Which is essentially the sticky protein plaques that build up in the brains of Alzheimer's patients.

SPEAKER_00 3:05

Aaron Powell Right. The plaques disrupt cell function, and the drugs are designed to clear that out.

SPEAKER_01 3:10

Aaron Powell But the clinical trials proving they can do this, they only lasted 18 months, which is, I mean, it's nothing when you consider the disease. Alzheimer's is a lifetime journey for a patient.

SPEAKER_00 3:22

Aaron Powell Yeah. 18 months is just a tiny snapshot.

SPEAKER_01 3:24

Aaron Powell So imagine you know, imagine being asked to fund a massive 30-year bridge construction project. It's going to cost billions in taxpayer money. But the engineers are only allowed to show you the first 18 months of weather data.

SPEAKER_00 3:37

Aaron Powell And maybe a few initial stress tests.

SPEAKER_01 3:39

Right. How on earth can a government know the bridge is safe for the long haul based on just that? They can't.

SPEAKER_00 3:45

That bridge analogy really captures the time gap perfectly. But it's actually even trickier than that because with a bridge, the laws of physics are constant, right? With the human brain, the rate of cognitive decay accelerates unpredictably. So in health economics, we refer to this specific uncertainty as the problem of meaningfulness.

SPEAKER_01 4:06

Aaron Ross Powell Meaningfulness. Like does the data actually mean anything in the real world?

SPEAKER_00 4:10

Aaron Ross Powell Exactly. Yes. The clinical trial shows statistically significant changes in cognitive test scores at the 18-month mark. But an 18-month snapshot of a, you know, slightly better memory test doesn't automatically translate to meaningfulness over a decade.

SPEAKER_01 4:24

Aaron Powell So it doesn't guarantee they'll stay independent.

SPEAKER_00 4:26

Aaron Powell Right. It doesn't guarantee that a patient will maintain their functioning years down the line. Will they still be able to dress themselves in seven years? Will they recognize their grandchildren?

SPEAKER_01 4:35

Aaron Ross Powell Wow, yeah. The 18-month data just can't answer that.

SPEAKER_00 4:38

Aaron Powell It simply cannot answer those human-level questions with the certainty required to like write a blank check from a national health budget.

SPEAKER_01 4:46

Aaron Powell So we have this incredible tension here. We obviously can't fast forward time to see if the drugs keep people independent for their whole lives. And we can't just pause treatment and wait 30 years for long-term trial data while people are getting sick today.

SPEAKER_00 5:00

Which puts governments in a really tough spot.

SPEAKER_01 5:02

Aaron Powell Exactly. If governments are forced to decide if these drugs are worth the money right now, they essentially have to predict the future.

Predicting Decades With Micro-Simulations

SPEAKER_01 5:09

Which brings us to the next big topic from the Glasgow Conference.

SPEAKER_00 5:13

Building complex predictive models. Since we lack that long-term empirical data, we have to mathematically simulate the remainder of a patient's life to estimate the value of the drug.

SPEAKER_01 5:24

Aaron Powell And the conference highlighted that the old ways of doing this simply aren't going to cut it anymore. They're moving toward entirely new micro-simulation model designs.

SPEAKER_00 5:35

Aaron Powell Yes. The innovations here are really fascinating.

SPEAKER_01 5:38

Aaron Powell I was looking at that section in the text on predictive modeling and I just couldn't wrap my head around it. How are they using things like advanced statistics and deep learning to predict a decade of Alzheimer's from a year and a half of data? Like how does a micro simulation actually work?

SPEAKER_00 5:52

Aaron Ross Powell So think of it as creating thousands of virtual patients inside a computer. Aaron Ross Powell Okay.

SPEAKER_01 5:56

Like digital twins.

SPEAKER_00 5:57

Aaron Ross Powell Kind of, yeah. Instead of looking at broad averages, a micro simulation assigns specific traits to a virtual individual. Their age, the genetic risk factors, their baseline cognitive score.

SPEAKER_01 6:09

Aaron Ross Powell And then what? It just presses play.

SPEAKER_00 6:12

Essentially. Using advanced statistical models drawn from decades of natural disease progression data, the system runs a simulation of how that specific virtual patient might fare over the next 10 or 20 years, both with and without the drug.

SPEAKER_01 6:26

Oh wow. And where does the AI fit into this?

SPEAKER_00 6:29

Well, the deep learning AI aspect comes in by feeding it massive historical data sets. This allows the AI to map out nonlinear relationships and like really subtle patterns of cognitive decline that traditional statistics might just miss.

SPEAKER_01 6:43

Okay, that makes sense. But and here's where it gets really interesting. Even with AI, if you're only measuring the medical costs like hospital beds and doctor visits, the math still seems heavily skewed against funding the drug.

Counting Caregiver Burden In Value

SPEAKER_00 6:55

Which is why the source emphasizes a huge shift in what these models are finally choosing to measure.

SPEAKER_01 7:00

Exactly. They are trying to rigorously quantify the health-related quality of life of informal caregivers.

SPEAKER_00 7:06

And I have to say, this is a fundamental game changer for economic calculations. I mean, the transparency, the open sourcing, and the cross-country validation of these new models, it's just incredible.

SPEAKER_01 7:18

You sound genuinely excited about the open sourcing part.

SPEAKER_00 7:20

Well, absolutely. Because for decades, health economic models have struggled to capture the true holistic cost of Alzheimer's by finally incorporating improved estimates of caregiver utility and by actually calculating caregiving time across the entire spectrum of the disease.

SPEAKER_01 7:38

It changes the math completely.

SPEAKER_00 7:39

It brings the math so much closer to reality.

SPEAKER_01 7:42

It's kind of like calculating the cost of a car accident. If the insurance company only looks at the dent in the bumper, the cost is what, a few hundred bucks.

SPEAKER_00 7:49

Right.

SPEAKER_01 7:50

But if they factor in the wages loss because the driver couldn't commute to work for a month, the true economic impact is massively higher.

SPEAKER_00 7:58

That's a really great analogy.

SPEAKER_01 8:00

Right. Because if your AI model captures the fact that a drug might keep an Alzheimer's patient independent for two extra years, that means their spouse can stay in the workforce for two extra years.

SPEAKER_00 8:10

Exactly. It means preserving the spouse's mental and physical health too.

SPEAKER_01 8:15

Suddenly, the economic value of paying for that drug skyrockets. Yeah. Because you're preventing a secondary health crisis in the caregiver.

SPEAKER_00 8:22

The unpaid toll of Alzheimer's is just staggering. Quantifying it gives a much more accurate picture of a drug's overall societal

The Diagnostic Cost Trap

SPEAKER_00 8:30

value.

SPEAKER_01 8:30

Aaron Powell But it's not all perfectly solved yet, is it?

SPEAKER_00 8:33

No, definitely not. We have to balance that out with another modeling headache discussed at the conference, which is the diagnostic dilemma.

SPEAKER_01 8:40

Ah, right. Because a systematic review presented at IPCAD underscored that you have to separate the economic value of the biomarker diagnostics from the value of the therapies themselves.

SPEAKER_00 8:51

Yes. Because you can't just hand this highly specific drug out to anyone who, you know, feels forgetful.

SPEAKER_01 8:57

Right. You have to prove they actually have the specific amyloid pathology, the physical plaques that the drug targets.

SPEAKER_00 9:04

And testing for those biological markers is incredibly complex and expensive. It requires advanced diagnostics like PEAT scans of the brain or lumbar punctures to test cerebrospinal fluid.

SPEAKER_01 9:14

Aaron Powell The budget impact of simply identifying the target population is astronomical.

SPEAKER_00 9:19

Aaron Powell It really is. Health systems have to model the diagnostic strategies to efficiently find these patients, and that upfront cost is a massive barrier.

SPEAKER_01 9:28

Aaron Powell Just to give you a sense of scale for that. If a government health system has to pay for, say, 10,000 advanced spinal taps and brain scans just to find the 500 specific people who actually qualify for the therapy. Trevor Burrus, Jr.

SPEAKER_00 9:42

The healthcare system basically goes bankrupt on testing before the first dose of the drug is even administered.

SPEAKER_01 9:47

Aaron Powell Exactly. Which is why the diagnostic cost has to be factored into the overall economic evaluation, the package deal.

SPEAKER_00 9:53

Aaron Powell And it remains a massive topic for debate among health economists.

SPEAKER_01 9:56

Aaron Powell Okay, but let me stop you there because I have to look at this with a bit of skepticism. Let's say we build the absolute perfect AI-driven micro-simulation. It accounts for the caregivers' lost wages, it perfectly models the cost of the PET scans, everything.

SPEAKER_00 10:10

Okay.

SPEAKER_01 10:11

At the end of the day, it is still just a theoretical prediction. It's a computer guessing the future. If I feed an AI bad assumptions, it's just going to give me very confident, very bad guesses.

SPEAKER_00 10:20

That is a very fair point.

SPEAKER_01 10:22

Aaron Powell So how do we actually verify these models without waiting 30 years to see if they were right?

Real-World Evidence And CED

SPEAKER_00 10:27

Aaron Powell Well, you verify theoretical models with real-world evidence, or RWE. You observe what happens outside the sterile, perfectly controlled environment of a clinical trial.

SPEAKER_01 10:37

Aaron Powell By looking at what's happening in hospitals right now.

SPEAKER_00 10:40

Right. Because different countries are approving and introducing these therapies at different times, we are basically watching a natural experiment unfold in real time. This phased global implementation allows us to learn from early adopters.

SPEAKER_01 10:54

The source material actually points to the United States as a prime example of this. The text says U.S. regulators are using something called CED, which is coverage with evidence development.

SPEAKER_00 11:04

Yes, CED. It essentially means the government says, we will pay for this drug, but only if the patients receiving it are enrolled in a registry.

SPEAKER_01 11:12

So they can track them and learn as they go.

SPEAKER_00 11:14

Exactly. It is a pragmatic compromise. It allows patient access right now while demanding continuous mandatory data collection to eventually resolve that uncertainty about long-term meaningfulness we talked about earlier.

SPEAKER_01 11:26

Aaron Powell Wait, but how is that actually supposed to yield good data? I mean, clinical trials are the gold standard because they're tightly controlled, randomized, double blind.

SPEAKER_00 11:35

They are.

SPEAKER_01 11:35

But the real world is a mess. If a patient in rural Texas eats differently, has a different baseline health, and misses half their clinic appointments compared to a patient in like an urban center in Europe, you can't just mash their spreadsheet data together and call it science.

SPEAKER_00 11:51

No, you definitely can't.

SPEAKER_01 11:52

Registries are non-randomized. So how can we possibly trust that data to be unbiased and high quality? Plus, aren't registries super expensive and operationally complex to run?

SPEAKER_00 12:04

You've hit on the exact statistical nightmare that occupied a huge portion of the IPCAD meeting. Those are valid structural flaws with real-world registries.

SPEAKER_01 12:14

Uncontrolled variables can completely skew your understanding of whether a drug is actually working.

SPEAKER_00 12:19

Exactly. But what's fascinating here is how the global community is mobilizing to solve that exact

Standardizing Data With INRAD

SPEAKER_00 12:25

problem. And the source points specifically to the Inner Rod Foundation.

SPEAKER_01 12:29

The International Registry for Alzheimer's Disease and Other Dementias.

SPEAKER_00 12:32

Right.

SPEAKER_01 12:40

So what are they doing differently to fix the messy data problem?

SPEAKER_00 12:44

Well, instead of every hospital using different software, asking different questions, and measuring different cognitive baselines.

SPEAKER_01 12:51

Which would be a total nightmare to combine.

SPEAKER_00 12:53

Exactly. INRAD establishes a harmonized framework. If you can standardize the variables you are collecting across borders, statisticians can use advanced techniques like propensity score matching to filter out the noise.

SPEAKER_01 13:06

Propensity score matching. Yeah. So you mathematically adjust for the fact that the patient in Texas has a different diet than the patient in Europe.

SPEAKER_00 13:12

Precisely. By pooling harmonized data globally, you vastly increase your sample size. And that scale gives you the statistical power to mimic the insights of a randomized trial, but using non-randomized real-world data.

SPEAKER_01 13:25

All right. So let's say INRAD solves the data problem. The AI models are validated by the real world registries. The health economists are totally satisfied. The governments open their checkbooks, and the drugs are fully funded.

SPEAKER_00 13:37

Okay, the ideal scenario.

SPEAKER_01 13:39

Right. The money is there. But if I walk into my local hospital tomorrow, can they actually give it to me?

SPEAKER_00 13:44

Based on the findings from patient groups and clinical initiatives at the conference, the resounding

Infrastructure Shortages Block Access

SPEAKER_00 13:50

answer is no. Wow.

SPEAKER_01 13:52

Even with the funding.

SPEAKER_00 13:53

Even with the funding, we are facing a massive infrastructure crisis. The healthcare systems themselves are fundamentally unprepared to deliver this care at scale.

SPEAKER_01 14:03

The required infrastructure just doesn't exist. I mean, the text lists a severe lack of diagnostic capacity for biomarker testing as a primary bottleneck. Most standard clinics simply aren't equipped to do advanced PD scans or lumbar punctures routinely.

SPEAKER_00 14:18

They aren't. And even if you get diagnosed, there are massive administration hurdles for the amyloid targeting therapies themselves. These aren't pills you can just, you know, take at home with your morning coffee.

SPEAKER_01 14:29

Right. They often require regular intravenous infusions at specialized clinics.

SPEAKER_00 14:33

Exactly. And because of those severe side effects we mentioned earlier, the risks of brain swelling or bleeding patients require intense, ongoing safety monitoring with regular MRI scans.

SPEAKER_01 14:43

It's like inventing a brilliant revolutionary fleet of electric vehicles for a country that hasn't built a single charging station.

SPEAKER_00 14:51

That's spot on.

SPEAKER_01 14:52

The cards might be absolute engineering marvels, but they are completely useless to the public if you can't plug them in anywhere.

SPEAKER_00 15:00

And that is the reality on the ground right now. And the infrastructure deficit is compounded by severe workforce limitations.

SPEAKER_01 15:06

Right, the specialists.

SPEAKER_00 15:07

Yeah, there simply aren't enough specialized neurologists to diagnose the sudden influx of eligible patients, nor are there enough trained nurses to staff the infusion centers and monitor the MRIs.

SPEAKER_01 15:19

Which creates massive geographic variability.

SPEAKER_00 15:21

Exactly. If you live next to a major research hospital in a wealthy urban center, perhaps you get the drug.

SPEAKER_01 15:27

But if you live in a rural area, the physical distance to a specialized infusion center might just lock you out of treatment entirely.

SPEAKER_00 15:35

Even if the dro is fully funded by your government.

SPEAKER_01 15:37

Which means what the representatives at the Glasgow conference were truly calling for goes way beyond just, you know, approving a budget.

Brain Health Shift And Global Inequity

SPEAKER_01 15:45

It requires a fundamental cultural change within healthcare providers.

SPEAKER_00 15:49

If we connect this to the bigger picture, we really have to completely overhaul how we think about this disease. We are shifting from a paradigm of palliative dementia care, which is essentially just helping people decline as comfortably as possible, to a proactive domain of brain health.

SPEAKER_01 16:06

And the text emphasizes that this requires building entirely new delivery pathways, focusing on risk factor management for primary prevention, early detection through accessible biomarkers, and then finally the drug treatment.

SPEAKER_00 16:19

It is a systemic reimagining of neurology.

SPEAKER_01 16:22

And we really have to acknowledge a deeply sobering fact highlighted in the source material regarding global disparity, because everything we've discussed so far, the advanced AI models, the real world registries, the specialized infusion clinics.

SPEAKER_00 16:35

That is largely a conversation happening in high-income nations.

SPEAKER_01 16:38

Exactly. In low and middle-income countries, the situation is incredibly dire.

SPEAKER_00 16:43

It is. The sheer lack of localized health economic evidence specific to their populations makes it nearly impossible for their governments to assess whether the current drug prices are justified.

SPEAKER_01 16:53

They just don't have the data to feed the models.

SPEAKER_00 16:55

Let alone the infrastructure to deliver the treatments. Consequently, they are entirely locked out of this new era of medicine, creating a stark global inequity.

SPEAKER_01 17:04

It's a really tough reality. So, what does this all mean for you listening? We've journeyed from the miraculous arrival of amyloid targeting drugs all the way to the harsh reality of health economics, predictive AI models, and the lack of physical hospital infrastructure.

SPEAKER_00 17:20

The big takeaway is that science moving fast means society has to scramble to catch up.

SPEAKER_01 17:25

Right. The entire paradigm is shifting toward a comprehensive brain health perspective. This means integrating early risk identification, securing biomarker diagnoses long before severe symptoms show, and fundamentally valuing the economic impact on informal caregivers.

SPEAKER_00 17:40

And the ultimate key to getting these drugs to patients faster is generating robust, standardized global evidence. We have to prove that clearing that brain plaque today actually leads to real world independence a decade from now.

SPEAKER_01 17:52

The scientific breakthrough was only the first step. The next great challenge is an economic and logistical one. Refining our mathematical evaluation of these interventions and building the physical clinics so that the care actually reaches the people who need it.

SPEAKER_00 18:07

Exactly.

Presymptomatic Diagnosis Ethical Shock

SPEAKER_01 18:08

But I want to leave you with a final provocative thought to mull over. And this builds directly on attention highlighted in the source material. We talked earlier about the need to separate the value of diagnostics from the therapies themselves.

SPEAKER_00 18:20

Right. The diagnostic dilemma.

SPEAKER_01 18:22

Yeah. And the text notes that future models will increasingly have to incorporate pre-symptomatic stages.

SPEAKER_00 18:28

Which is fascinating. It is.

SPEAKER_01 18:30

So imagine a near future, maybe just a few years away, where advanced low-cost diagnostic screening for Alzheimer's biomarkers becomes widely available. Say it's just like a simple blood test at your annual checkup.

SPEAKER_00 18:42

Which researchers are actively working on.

SPEAKER_01 18:44

Exactly. So that test catches the amyloid plaques building up in your brain a full decade before you ever forget a name or misplace your keys. But what happens to society when millions of perfectly healthy-feeling people are handed a highly accurate presymptomatic Alzheimer's diagnosis, only for their national health system to tell them, we know you have the plaques and the treatment exists, but the economic models say we still can't afford to give it to you yet. Wow. How will we cope with a world full of biological ticking clocks and locked medicine cabinets?

SPEAKER_00 19:18

It is a profound societal challenge. And our economic models and our healthcare infrastructure are accelerating toward it very, very quickly.

SPEAKER_01 19:25

It really is. Thank you for joining us on this deep dive into the complex world of Alzheimer's health economics. Keep exploring the sources, keep reading, and keep asking the tough questions. We'll catch you next time.